A Phase 1 Open Label Study Evaluating the Distribution of a Tenofovir Douche in Combination With Tap Water Douching and Simulated Receptive Anal Intercourse (DREAM-02)
Latest Information Update: 18 Jan 2023
Price :
$35 *
At a glance
- Drugs Tenofovir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Acronyms DREAM-02
- 12 Jan 2023 Status changed from recruiting to completed.
- 14 Oct 2022 Planned End Date changed from 31 Oct 2022 to 31 Dec 2022.
- 14 Oct 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Dec 2022.